Cited by 2,517Prostate Cancer Treatment and ResearchCancer Genomics and DiagnosticsChromatin Remodeling and Cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

The mutational landscape of lethal castration-resistant prostate cancer

Open access

Grasso, Catherine S., Wu, Yi-Mi, Robinson, Dan R., Cao, Xuhong, Dhanasekaran, Saravana M., Khan, Amjad P., Quist, Michael J., Jing, Xiaojun, Lonigro, Robert J., Brenner, J. Chad, Asangani, Irfan A., Ateeq, Bushra, Chun, Sang Y., Siddiqui, Javed, Sam, Lee, Anstett, Matt, Mehra, Rohit, Prensner, John R., Palanisamy, Nallasivam, Ryslik, Gregory A., Vandin, Fabio, Raphael, Benjamin J., Kunju, Lakshmi P., Rhodes, Daniel R., Pienta, Kenneth J., Chinnaiyan, Arul M., Tomlins, Scott A.·2012·Nature

DOI 10.1038/nature11125PMC PMC3396711

Open this paper in CoChat — free account

Abstract

Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11125

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citation
An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citation
A Hierarchical Network of Transcription Factors Governs Androgen Receptor-Dependent Prostate Cancer Growth
Wang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citation
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568

Flagged first, then by citations

Show all 23 references

Sorted by citations

Items 301–400 of 1,005

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
Wang, Z., Wang, Y., Zhang, J., Hu, Q., Zhi, F., Zhang, S., Mao, D., Zhang, Y., & Liang, H. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7281 · Cited by 119
Synthesis and anticancer activity of novel water soluble benzimidazole carbamates
Cheong, J. E., Zaffagni, M., Chung, I., Xu, Y., Wang, Y., Jernigan, F. E., Zetter, B. R., & Sun, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.037 · Cited by 119
NSD2 is a conserved driver of metastatic prostate cancer progression
Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 122
Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression
Blessing, A. M., Rajapakshe, K., Bollu, L. R., Shi, Y., White, M. A., Pham, A. H., Lin, C., Jonsson, P., Cortés, C. J., Cheung, E. C. W., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1268300 · Cited by 120
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology
Wiesel‐Motiuk, N., & Assaraf, Y. G. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100729 · Cited by 121
The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer
Lindberg, J., Mills, I. G., Klevebring, D., Liu, W., Neiman, M., Xu, J., Wikström, P., Wiklund, P. N., Wiklund, F. E., Egevad, L., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.11.053 · Cited by 117
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Schmid, S., Omlin, A. G., Higano, C. S., Sweeney, C. J., Chanzá, N. M., Mehra, N., Kuppen, M. C. P., Beltran, H., Conteduca, V., de Almeida, D. V. P., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.21692 · Cited by 118
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state
Chi, K. N., Hotte, S. J., Joshua, A. M., North, S. A., Wyatt, A. W., Collins, L. L., & Fred Saad, C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv267 · Cited by 117
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 119
Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer
Zhao, D., Cai, L., Lü, X., Liang, X., Li, J., Chen, P., Ittmann, M., Shang, X., Jiang, S., Li, H., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1352 · Cited by 116
Global footprints of organochlorine pesticides: a pan-global survey
Keswani, C., Dilnashin, H., Birla, H., Roy, P., Tyagi, R. K., Singh, D., Rajput, V. D., Minkina, T., & Singh, S. P. (2021) · Environmental Geochemistry and Health · doi:10.1007/s10653-021-00946-7 · Cited by 116
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
García-Vílchez, R., Añazco-Guenkova, A. M., Dietmann, S., López, J., Morón-Calvente, V., D’Ambrosi, S., Nombela, P., Zamacola, K., Mendizabal, I., Garcia‐Longarte, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01809-8 · Cited by 118
Molecular pathways and targets in prostate cancer
Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 116
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 121
MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2
Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., Zhao, S. G., Hanson, A. R., Pickering, M. A., Armstrong, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-2529 · Cited by 116
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2 : CALGB 151111 (Alliance)
Augert, A., Zhang, Q., Bates, B. M., Cui, M., Wang, X., Wildey, G. M., Dowlati, A., & MacPherson, D. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.011 · Cited by 115
Revisiting the role of Wnt/β-catenin signaling in prostate cancer
Schneider, J. A., & Logan, S. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.008 · Cited by 115
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Chakraborty, G., Armenia, J., Mazzu, Y. Z., Nandakumar, S., Stopsack, K. H., Atiq, M. O., Komura, K., Jehane, L. E., Hirani, R., Chadalavada, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1570 · Cited by 116
Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF
Takayama, K., Suzuki, T., Fujimura, T., Yamada, Y., Takahashi, S., Homma, Y., Suzuki, Y., & Inoue, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706076114 · Cited by 114
FOXO family isoforms
Santos, B., Grenho, I., Martel, P. J., Ferreira, B. I., & Link, W. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06177-1 · Cited by 118
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness
Kari, V., Mansour, W. Y., Raul, S. K., Baumgart, S. J., Mund, A., Grade, M., Sirma, H., Simon, R., Will, H., Dobbelstein, M., et al. (2016) · EMBO Reports · doi:10.15252/embr.201642352 · Cited by 115
Organ-Specific Cancer Metabolism and Its Potential for Therapy
Elia, I., Schmieder, R., Christen, S., & Fendt, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_10 · Cited by 112
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Therapeutic Approaches Targeting MYC-Driven Prostate Cancer
Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017) · Genes · doi:10.3390/genes8020071 · Cited by 110
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
Zhang, J., Zhou, N., Lin, A., Luo, P., Chen, X., Deng, H., Kang, S., Guo, L., Zhu, W., & Zhang, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02668-8 · Cited by 110
Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer
Paltoglou, S. M., Das, R., Townley, S. L., Hickey, T. E., Tarulli, G. A., Coutinho, I., Fernandes, R. C., Hanson, A. R., Denis, I., Carroll, J. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1616 · Cited by 108
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome
Liu, X., Grogan, T., Hieronymus, H., Hashimoto, T., Mottahedeh, J., Cheng, D., Zhang, L., Huang, K. Y., Stoyanova, T. I., Park, J. W., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.010 · Cited by 107
Extracellular vesicles in urological malignancies: an update
Linxweiler, J., & Junker, K. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0261-8 · Cited by 107
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
Vatapalli, R. J., Sagar, V., Rodríguez, Y., Zhao, J. C., Unno, K., Pamarthy, S., Lysy, B., Anker, J. F., Han, H., Yoo, Y. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18013-7 · Cited by 111
BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Shah, S., Rachmat, R., Enyioma, S., Ghose, A., Revythis, A., & Boussios, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312628 · Cited by 113
The hallmarks of castration-resistant prostate cancers
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., de Villeneuve, M. H., & Rocchi, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.003 · Cited by 118
Notch3 Functions as a Tumor Suppressor by Controlling Cellular Senescence
Cui, H., Kong, Y., Xu, M., & Zhang, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3902 · Cited by 106
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Iglesias-Gato, D., Thysell, E., Tyanova, S., Crnalic, S., Santos, A., Lima, T. S., Geiger, T., Cox, J., Widmark, A., Bergh, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1229 · Cited by 106
KDM4B as a Target for Prostate Cancer: Structural Analysis and Selective Inhibition by a Novel Inhibitor
Chu, C., Wang, L., Hsu, K., Chen, C.-C., Cheng, H.-H., Wang, S.-M., Wu, C.-M., Chen, T., Li, L.-T., Liu, R., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500249n · Cited by 106
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival
Fan, L., Peng, G., Sahgal, N., Fazli, L., Gleave, M. E., Zhang, Y., Hussain, A., & Qi, J. (2015) · Oncogene · doi:10.1038/onc.2015.309 · Cited by 106
miR‐200/375 control epithelial plasticity‐associated alternative splicing by repressing the RNA‐binding protein Quaking
Pillman, K. A., Phillips, C. A., Roslan, S., Toubia, J., Dredge, B. K., Bert, A. G., Lumb, R., Neumann, D., Li, X., Conn, S. J., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899016 · Cited by 107
The Landscape of Immune Cells Infiltrating in Prostate Cancer
Wu, Z., Chen, H., Luo, W., Zhang, H., Li, G., Zeng, F., & Deng, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.517637 · Cited by 109
Prostate cancer treatment – China's perspective
Liu, J., Dong, L., Zhu, Y., Dong, B., Sha, J., Zhu, H. H., Pan, J., & Xue, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215927 · Cited by 107
JMJD family proteins in cancer and inflammation
Wang, M., Jianxin, X., Hong, W., Chen, S., & Huashan, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01145-1 · Cited by 106
Inhibition of androgen receptor and β-catenin activity in prostate cancer
Lee, E., Madar, A., David, G., Garabedian, M. J., DasGupta, R., & Logan, S. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218168110 · Cited by 103
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review
Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 104
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells
Tomida, J., Takata, K., Bhetawal, S., Person, M. D., Chao, H., Tang, D. G., & Wood, R. D. (2018) · The EMBO Journal · doi:10.15252/embj.201899543 · Cited by 106
Characterizing CDK12-Mutated Prostate Cancers
Rescigno, P., Gürel, B., Pereira, R., Crespo, M., Rekowski, J., Rediti, M., Barrero, M., Mateo, J., Bianchini, D., Messina, C. G. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2371 · Cited by 102
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 100
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression
Jin, R., Yamashita, H., Yu, X., Wang, J., Franco, O. E., Wang, Y., Hayward, S. W., & Matusik, R. J. (2014) · Oncogene · doi:10.1038/onc.2014.302 · Cited by 104
RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten -Mutant Metastasis
Cho, H., Herzka, T. M., Wu, Z., Qi, J., Wilkinson, J. E., Bradner, J. E., Robinson, B. D., Castillo-Martín, M., Cordon‐Cardo, C., & Trotman, L. C. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0346 · Cited by 102
Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis
Deep, G., & Schlaepfer, I. R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071061 · Cited by 101
The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy
Erdoğan, S., Turkekul, K., Serttas, R., & Erdoğan, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.056 · Cited by 102
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
Kallio, H. M. L., Hieta, R., Latonen, L., Brofeldt, A., Annala, M., Kivinummi, K. K., Tammela, T. L. J., Nykter, M., Isaacs, W. B., Lilja, H. G., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0172-0 · Cited by 103
A molecular portrait of epithelial–mesenchymal plasticity in prostate cancer associated with clinical outcome
Stylianou, N., Lehman, M., Wang, C., Fard, A. T., Rockstroh, A., Fazli, L., Jovanovic, L., Ward, M. S., Sadowski, M. C., Kashyap, A. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0488-5 · Cited by 101
2‐Isoxazolines: A Synthetic and Medicinal Overview
Kumar, G., & Shankar, R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000575 · Cited by 100
Chromatin and oxygen sensing in the context of JmjC histone demethylases
Shmakova, A., Batie, M., Druker, J., & Rocha, S. (2014) · Biochemical Journal · doi:10.1042/bj20140754 · Cited by 99
Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Zhang, Y., Liu, B., Wu, W., Li, L., Broom, B. M., Basourakos, S. P., Korentzelos, D. K., Luan, Y., Wang, J., Yang, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1872 · Cited by 102
Self-citation
The role of JNK in prostate cancer progression and therapeutic strategies
Xu, R., & Hu, J. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109679 · Cited by 102
Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
Robinson, J. L. L., Hickey, T. E., Warren, A. Y., Vowler, S. L., Carroll, T., Lamb, A. D. G., Papoutsoglou, N., Neal, D. E., Tilley, W. D., & Carroll, J. S. (2013) · Oncogene · doi:10.1038/onc.2013.508 · Cited by 99
β-Catenin Is Required for Prostate Development and Cooperates with Pten Loss to Drive Invasive Carcinoma
Francis, J. C., Thomsen, M. K., Taketo, M. M., & Swain, A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003180 · Cited by 99
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Antonarakis, E. S., & Boudadi, K. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34534 · Cited by 101
miR-539 inhibits prostate cancer progression by directly targeting SPAG5
Zhang, H., Li, S., Yang, X., Qiao, B., Zhang, Z., & Xu, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0337-8 · Cited by 98
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited
Deek, M. P., der Eecken, K. V., Phillips, R., Parikh, N. R., Velho, P. I., Lotan, T. L., Kishan, A. U., Maurer, T., Boutros, P. C., Hovens, C. M., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.12.040 · Cited by 98
Self-citation
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability
Munkley, J., Vodák, D., Livermore, K. E., James, K., Wilson, B. T., Knight, B., McCullagh, P. J., McGrath, J. S., Crundwell, M. C., Harries, L. W., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.018 · Cited by 100
EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate Cancer
Wee, Z. N., Li, Z., Lee, P. L., Lee, S. T., Lim, Y. P., & Yu, Q. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.045 · Cited by 101
Calcium Permeable Channels in Cancer Hallmarks
Tajada, S., & Villalobos, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00968 · Cited by 102
Targeted genomic sequencing of follicular dendritic cell sarcoma reveals recurrent alterations in NF-κB regulatory genes
Griffin, G. K., Sholl, L. M., Lindeman, N. I., Fletcher, C. D. �., & Hornick, J. L. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.130 · Cited by 97
miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression
Zhang, H., Qi, S., Zhang, T., Wang, A., Liu, R., Guo, J., Wang, Y. Z., & Xu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3341 · Cited by 96
Methodological aspects and pharmacological applications of three-dimensional cancer cell cultures and organoids
Foglietta, F., Canaparo, R., Muccioli, G., Terreno, E., & Serpe, L. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117784 · Cited by 101
Extensive cellular heterogeneity of X inactivation revealed by single-cell allele-specific expression in human fibroblasts
Garieri, M., Stamoulis, G., Blanc, X., Falconnet, E., Ribaux, P., Borel, C., Santoni, F. A., & Antonarakis, S. E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806811115 · Cited by 96
The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics
Abdel-Wahab, O. I., & Dey, A. (2012) · Leukemia · doi:10.1038/leu.2012.288 · Cited by 97
Androgen receptor genomic regulation.
Jin, H., Kim, J., & Yu, J. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2223-4683.2013.09.01 · Cited by 103
CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets
Cortázar, A. R., Torrano, V., Martín-Martín, N., Caro‐Maldonado, A., Camacho, L., Heřmanová, I., Guruceaga, E., Lorenzo‐Martín, L. F., Caloto, R., Gomis, R. R., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1669 · Cited by 95
The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression
Chakravarthi, B. V. S. K., Pathi, S. S., Goswami, M. T., Cieslik, M. P., Zheng, H., Nallasivam, S., Arekapudi, S. R., Jing, X., Siddiqui, J., Athanikar, J. N., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2208 · Cited by 95
Self-citation
Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 98
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
Beer, T. M., Hotte, S. J., Fred Saad, C., Alekseev, B. Y., Matveev, V. B., Fléchon, A., Gravis, G., Joly, F., Chi, K. N., Malik, Z., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30605-8 · Cited by 94
Genetic Alterations of TRAF Proteins in Human Cancers
Zhu, S., Jin, J., Gokhale, S., Lu, A. M., Shan, H., Feng, J., & Xie, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02111 · Cited by 96
A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone
Wang, L., Dehm, S. M., Hillman, D. W., Sicotte, H., Tan, W. W., Gormley, M., Bhargava, V., Jiménez, R. E., Xie, F., Yin, P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx689 · Cited by 94
KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer
Gao, L., Zhang, W., Zhang, J., Liu, J., Sun, F., Liu, H., Hu, J., Wang, X., Wang, X., Su, P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1965 · Cited by 94
Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer
Drake, J. M., Lee, J. K., & Witte, O. N. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01592-13 · Cited by 94
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH
Lotan, T. L., Wei, W., Ludkovski, O., Morais, C. L., Guedes, L. B., Jamaspishvili, T., Lopez, K., Hawley, S. T., Feng, Z., Fazli, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.88 · Cited by 92
Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer
Schneider, J. A., Craven, T. W., Kasper, A. C., Yun, C., Haugbro, M., Briggs, E. M., Svetlov, V. V., Nudler, E., Knaut, H., Bonneau, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06845-3 · Cited by 94
Cellular rewiring in lethal prostate cancer: the architect of drug resistance
Carceles‐Cordon, M., Kelly, W. K., Gomella, L. G., Knudsen, K. E., Rodríguez-Bravo, V., & Domenech, J. M. D. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0298-8 · Cited by 97
GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers
Wang, J., Xu, W., Wang, B., Lin, G., Yu, W., Abudurexiti, M., Zhu, W., Liu, C., Qin, X., Dai, B., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.007 · Cited by 92
The emerging role of speckle-type POZ protein (SPOP) in cancer development
Mani, R. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.009 · Cited by 92
Current perspectives on bone metastases in castrate-resistant prostate cancer
Logothetis, C. J., Morris, M. J., Den, R. B., & Coleman, R. E. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9719-4 · Cited by 91
BRCA2 and Other DDR Genes in Prostate Cancer
Nombela, P., Lozano, R., Aytés, À., Mateo, J., Olmos, D., & Castro, E. (2019) · Cancers · doi:10.3390/cancers11030352 · Cited by 93
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 96
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Tortorella, E., Giantulli, S., Sciarra, A., & Silvestri, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032046 · Cited by 96
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 96
EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
Carroll, J. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0124 · Cited by 96
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Chi, K. N., Higano, C. S., Blumenstein, B. A., Ferrero, J.-., Reeves, J. A., Feyerabend, S., Gravis, G., Merseburger, A. S., Stenzl, A., Bergman, A. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30168-7 · Cited by 90
Tumor‐infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
Krueger, T. E. G., Thorek, D. L. J., Meeker, A. K., Isaacs, J. T., & Brennen, W. N. (2018) · The Prostate · doi:10.1002/pros.23738 · Cited by 90
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yeh, Y. A., Guo, Q., Connelly, Z. M., Cheng, S., Yang, S., Prieto‐Domínguez, N., & Yu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_16 · Cited by 94
Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer
Kaushik, A., Shojaie, A., Panzitt, K., Sonavane, R., Venghatakrishnan, H., Manikkam, M., Zaslavsky, A., Putluri, V., Vasu, V. T., Zhang, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11612 · Cited by 89
Self-citation
RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage
Ho, S.-R., Mahanic, C. S., Lee, Y.-J., & Lin, W.-C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323107111 · Cited by 88
Advancing Precision Medicine for Prostate Cancer Through Genomics
Roychowdhury, S., & Chinnaiyan, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3662 · Cited by 88
Self-citation
Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data
Williams, J. L., Greer, P. A., & Squire, J. A. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.09.003 · Cited by 88
AR function in promoting metastatic prostate cancer
Augello, M. A., Den, R. B., & Knudsen, K. E. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9471-3 · Cited by 91
Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Tian, X., Zhang, S., Liu, H., Zhang, Y., Blair, C., Mercola, D., Sassone‐Corsi, P., & Zi, X. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313050007 · Cited by 90
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
Padmanabhan, A., Candelaria, N., Wong, K.-K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W., & Richards, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-03599-w · Cited by 88
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling
Zong, Y., Huang, J., Sankarasharma, D., Morikawa, T., Fukayama, M., Epstein, J. I., Chada, K. K., & Witte, O. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217982109 · Cited by 87
Algorithmic methods to infer the evolutionary trajectories in cancer progression
Caravagna, G., Graudenzi, A., Ramazzotti, D., Pamplona, R. S., Sano, L. D., Mauri, G., Moreno, V. R., Antoniotti, M., & Mishra, B. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520213113 · Cited by 89
Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
Tse, B. W.-C., Volpert, M., Ratther, E., Stylianou, N., Nouri, M., McGowan, K., Lehman, M., McPherson, S. J., Roshan‐Moniri, M., Butler, M. S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.482 · Cited by 87

Authors: Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
Affiliations: University of Michigan (US)
Howard Hughes Medical Institute (US)
Yale University (US)
Brown University (US)
Corresponding author: Pienta, Kenneth J.
Chinnaiyan, Arul M.
ORCID: Grasso, Catherine S.
Robinson, Dan R.
Cao, Xuhong
Dhanasekaran, Saravana M.
Khan, Amjad P.
Jing, Xiaojun
Brenner, J. Chad
Asangani, Irfan A.
Ateeq, Bushra
Siddiqui, Javed
Mehra, Rohit
Prensner, John R.
Palanisamy, Nallasivam
Ryslik, Gregory A.
Vandin, Fabio
Raphael, Benjamin J.
Kunju, Lakshmi P.
Rhodes, Daniel R.
Pienta, Kenneth J.
Chinnaiyan, Arul M.
Tomlins, Scott A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-05-20
Volume: 487
Issue: 7406
Pages: 239-243
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11125
PMC: PMC3396711
OpenAlex: W2051025382
Cited by: 2,517
References: 23
Citations by year: 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
FWCI: 152.73
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Padua Research Archive (University of Padova) (submittedVersion)
Funders: Howard Hughes Medical Institute
National Institutes of Health (5r01ca013287-14)
National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
MeSH terms: Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The mutational landscape of lethal castration-resistant prostate cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks